BUSINESSJul 13 · 10:15 UTCSCMP CHINAJulie Zhang

China’s drug industry pivots to AI-powered candidates to drive next wave of deals

China's cross-border deals for innovative drugs reached $110 billion in H1 2026, with the industry now focusing on AI-powered candidates to drive future transactions. China holds 30% of globally developed new drugs, ranking second worldwide, according to Lan Gongtao from the National Medical Products Administration.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Lan GongtaopersonNational Medical Products AdministrationorganizationDepartment of Drug RegistrationorganizationAI-powered candidatestopiccross-border dealstopicinnovative drugstopicChinaplace

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 13 · 10:15 UTC
China’s drug industry pivots to AI-powered candidates to drive next wave of deals
BUSINESSJul 2 · 11:00 UTC
China AI drug-design deals swell as US scrutiny mounts
BUSINESSMay 12 · 07:48 UTC
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
BUSINESSJul 2 · 11:00 UTC
China AI drug-design deals swell as US scrutiny mounts
BUSINESSMay 15 · 15:04 UTC
Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration
BUSINESSJun 3 · 11:06 UTC
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas